Changchun Hi-Tech announced that recently, its subsidiary Jinsai Pharmaceutical received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, and the application for registration of drugs produced domestically for GenSci 148 injection was approved. The indications are neovasculatory age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. This injection is a VEGF multi-blocker independently developed by Jinsai Pharmaceutical and is expected to provide more beneficial treatment options for related patients. However, there is uncertainty about the follow-up process and results of clinical trials.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.